Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Appointed director
Acq. announced

ASSEMBLY BIOSCIENCES, INC. (ASMB) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 144 Form 144 - Report of proposed sale of securities:
10/03/2023 144 Form 144 - Report of proposed sale of securities:
09/29/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates - Herpesvirus candidate ABI-5366 anticipated to enter clinic in first half of 2024 - New data for several pipeline programs presented at IHW and EASL 2023 - Additional development candidate nomination expected in 2023"
08/07/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
08/02/2023 144 Form 144 - Report of proposed sale of securities:
08/02/2023 144 Form 144 - Report of proposed sale of securities:
05/30/2023 144 Form 144 - Report of proposed sale of securities:
05/30/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "AMENDMENT NO. 6 TO ASSEMBLY BIOSCIENCES, INC. 2018 STOCK INCENTIVE PLAN Assembly Biosciences, Inc., a Delaware corporation adopted the 2018 Stock Incentive Plan on May 30, 2018, which was amended by Amendment No. 1 to Assembly Biosciences, Inc. 2018 Stock Incentive Plan effective as of May 17, 2019, by Omnibus Amendment to Assembly Biosciences, Inc. Stock Plans effective as of March 11, 2020, by Amendment No. 3 effective as of June 11, 2020, by Amendment No. 4 effective as of May 20, 2021 and Amendment No. 5 effective as of May 25, 2022 . Prior to this Amendment No. 6 to the Plan, the number of shares of Common Stock, par value $0.001 per share, reserved under the Plan was 8,600,000. The Board of Directors of the Company may, with stockholder approval, amend the Plan to increase the number..."
05/23/2023 144 Form 144 - Report of proposed sale of securities:
05/23/2023 144 Form 144 - Report of proposed sale of securities:
05/23/2023 144 Form 144 - Report of proposed sale of securities:
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
04/18/2023 8-K Quarterly results
04/17/2023 EFFECT Form EFFECT - Notice of Effectiveness:
03/31/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/22/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
03/22/2023 10-K Annual Report for the period ended December 31, 2022
03/22/2023 8-K Quarterly results
Docs: "ASSEMBLY BIOSCIENCES, INC. CONSOLIDATED BALANCE SHEETS December 30, December 31, 2022 2021 ASSETS Current assets Cash and cash equivalents $ 52,418 $ 45,627 Marketable securities - short-term 39,192 101,000 Accounts receivable from collaborations 944 336 Prepaid expenses and other current assets 4,413 7,241 Total current assets 96,967 154,204 Marketable securities - long-term — 27,972 Property and equipment, net 743 1,139 Operating lease right-of-use assets 3,195 6,042 Other assets 889 1,703 Total assets $ 101,794 $ 191,060 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 2,493 $ 2,659 Accrued research and development expenses 3,122 3,400 Other accrued expenses 7,317 6,863 Operating lease liabilities - short-term 3,364 3,151 Total current liabilities 16,296 16,07..."
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
12/19/2022 8-K Quarterly results
12/12/2022 8-K Quarterly results
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
Docs: "ASSEMBLY BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2022 2021 ASSETS Current assets Cash and cash equivalents $ 54,673 $ 45,627 Marketable securities - short-term 53,978 101,000 Accounts receivable from collaborations 1,246 336 Prepaid expenses and other current assets 5,181 7,241 Total current assets 115,078 154,204 Marketable securities - long-term — 27,972 Property and equipment, net 867 1,139 Operating lease right-of-use assets 3,958 6,042 Other assets 1,613 1,703 Total assets $ 121,516 $ 191,060 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 1,942 $ 2,659 Accrued research and development expenses 4,462 3,400 Other accrued expenses 5,686 6,863 Operating lease liabilities - short-term 3,371 3,151 Total current liabilit..."
10/05/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor Dr. McHutchison will continue to provide strategic counsel as board member and chairman of the Science & Technology Committee of the board SOUTH SAN FRANCISCO, Calif., October 5, 2022 – Assembly Biosciences, Inc. , a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus and other viral diseases, today announced that John G. McHutchison, AO, MD, chief executive officer , will retire as CEO at the end of 2022. Dr. McHutchison will continue to serve on Assembly Bio’s Board of Directors, including assuming the role of chairman of the Science and Technology Committee. Assembly Bio’s Board of Di..."
08/09/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Quarterly results
Docs: "Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif., August 9, 2022"
07/20/2022 8-K Quarterly results
05/27/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy